744 related articles for article (PubMed ID: 28346400)
1. T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy.
Sackstein R; Schatton T; Barthel SR
Lab Invest; 2017 Jun; 97(6):669-697. PubMed ID: 28346400
[TBL] [Abstract][Full Text] [Related]
2. Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.
Ascierto PA; Agarwala SS; Ciliberto G; Demaria S; Dummer R; Duong CPM; Ferrone S; Formenti SC; Garbe C; Halaban R; Khleif S; Luke JJ; Mir LM; Overwijk WW; Postow M; Puzanov I; Sondel P; Taube JM; Thor Straten P; Stroncek DF; Wargo JA; Zarour H; Thurin M
J Transl Med; 2017 Nov; 15(1):236. PubMed ID: 29145885
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
4. [Mechanisms of resistance and escape to CAR-T cells].
Grinda T; Brouard J; Tran D; Rubio MT
Bull Cancer; 2021 Oct; 108(10S):S128-S140. PubMed ID: 34920795
[TBL] [Abstract][Full Text] [Related]
5. Permissive expansion and homing of adoptively transferred T cells in tumor-bearing hosts.
Perez C; Jukica A; Listopad JJ; Anders K; Kühl AA; Loddenkemper C; Blankenstein T; Charo J
Int J Cancer; 2015 Jul; 137(2):359-71. PubMed ID: 25530110
[TBL] [Abstract][Full Text] [Related]
6. Co-transfer of tumor-specific effector and memory CD8+ T cells enhances the efficacy of adoptive melanoma immunotherapy in a mouse model.
Contreras A; Beems MV; Tatar AJ; Sen S; Srinand P; Suresh M; Luther TK; Cho CS
J Immunother Cancer; 2018 May; 6(1):41. PubMed ID: 29843822
[TBL] [Abstract][Full Text] [Related]
7. Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic.
Duong CP; Yong CS; Kershaw MH; Slaney CY; Darcy PK
Mol Immunol; 2015 Oct; 67(2 Pt A):46-57. PubMed ID: 25595028
[TBL] [Abstract][Full Text] [Related]
8. Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy.
Elia AR; Grioni M; Basso V; Curnis F; Freschi M; Corti A; Mondino A; Bellone M
Clin Cancer Res; 2018 May; 24(9):2171-2181. PubMed ID: 29490991
[No Abstract] [Full Text] [Related]
9. Gene modification strategies for next-generation CAR T cells against solid cancers.
Tian Y; Li Y; Shao Y; Zhang Y
J Hematol Oncol; 2020 May; 13(1):54. PubMed ID: 32423475
[TBL] [Abstract][Full Text] [Related]
10. Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators.
Hou J; Wang Y; Shi L; Chen Y; Xu C; Saeedi A; Pan K; Bohat R; Egan NA; McKenzie JA; Mbofung RM; Williams LJ; Yang Z; Sun M; Liang X; Rodon Ahnert J; Varadarajan N; Yee C; Chen Y; Hwu P; Peng W
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589527
[TBL] [Abstract][Full Text] [Related]
11. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
Maccalli C; Parmiani G; Ferrone S
Immunol Invest; 2017 Apr; 46(3):221-238. PubMed ID: 28287848
[TBL] [Abstract][Full Text] [Related]
13.
Hunger J; Schregel K; Boztepe B; Agardy DA; Turco V; Karimian-Jazi K; Weidenfeld I; Streibel Y; Fischer M; Sturm V; Santarella-Mellwig R; Kilian M; Jähne K; Sahm K; Wick W; Bunse L; Heiland S; Bunse T; Bendszus M; Platten M; Breckwoldt MO
Theranostics; 2023; 13(15):5170-5182. PubMed ID: 37908732
[No Abstract] [Full Text] [Related]
14. HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice.
Forsberg EMV; Lindberg MF; Jespersen H; Alsén S; Bagge RO; Donia M; Svane IM; Nilsson O; Ny L; Nilsson LM; Nilsson JA
Cancer Res; 2019 Mar; 79(5):899-904. PubMed ID: 30622115
[TBL] [Abstract][Full Text] [Related]
15. The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy.
Wang Y; Zhang H; He YW
Front Immunol; 2019; 10():1574. PubMed ID: 31379815
[TBL] [Abstract][Full Text] [Related]
16. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy.
Kumar A; Chamoto K; Chowdhury PS; Honjo T
Elife; 2020 Mar; 9():. PubMed ID: 32122466
[TBL] [Abstract][Full Text] [Related]
17. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
18. Mechanical Immunoengineering of T cells for Therapeutic Applications.
Lei K; Kurum A; Tang L
Acc Chem Res; 2020 Dec; 53(12):2777-2790. PubMed ID: 33258577
[TBL] [Abstract][Full Text] [Related]
19. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models.
Leone RD; Sun IM; Oh MH; Sun IH; Wen J; Englert J; Powell JD
Cancer Immunol Immunother; 2018 Aug; 67(8):1271-1284. PubMed ID: 29923026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
